Top 5 ASCO 2025 Myeloma Abstracts Suggested by Vincent Rajkumar
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, shared a post on X:
“Top 5 ASCO 2025 myeloma abstracts.
#5 Dara-KRd significantly higher MRD- rate versus KRd; 59% vs 36% — ADVANCE trial.
One more RCT establishing quadruplets (when feasible) as standard of care for newly diagnosed myeloma.
Title: Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.
Authors: Carl Landgren, Jing Ye, Jens Hillengass, Douglas Sborov, James Hoffman, Benjamin Diamond, David Coffey, Marcella Kaddoura, Abhishek Pandey, Kellye Koubek, Stephanie Mompoint, Sindy Gutierrez, Caterine Diaz, Michelle Armogan, Rachid Baz, Robert Orlowski, Thomas Jandl, Neha Korde, Kenneth Shain, Dickran Kazandjian
#4 ISB 2001 Trispecific CD3/BCMA/CD38 antibody.
5% response rate in phase I in refractory myeloma
Title: Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
Authors: Eben Lichtman, Amit Khot, Bradley Augustson, David Levitz, Hanlon Sia, Nicole Wong Doo, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Harjeet Sembhi, Maria Pihlgren, Cyril Konto, Beata Holkova, Lida Pacaud, Hang Quach
#3 JNJ-5322 Trispecific CD3/BCMA/GPRC5D antibody.
73% response rate including 66% VGPR overall in Phase I
Title: First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.
Authors: Niels van de Donk, Gala Vega, Aurore Perrot, Sébastien Anguille, Albert Oriol, Monique Minnema, Martin Kaiser, Hans Lee, Alfred Garfall, Jeffrey Matous, Larysa Sanchez, Azra Borogovac, Lionel Karlin, Saad Usmani, Joseph Weidman, Sangmin Lee, Maria-Victoria Mateos, Paula Rodríguez-Otero, Cyrille Touzeau, Rakesh Popat
#2 MIDAS trial
In patients MRD- after induction, auto transplant did not improve pre-maintenance MRD- rate compared to IsaKRD consolidation. In patients MRD+ after induction, tandem ASCT did not improve MRD – rate.
Title: MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.
Authors: Aurore Perrot, Cyrille Hulin, Jerome Lambert, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean Marc Schiano de Colella, Mohamad Mohty, Xavier Leleu, Salomon Manier, Herve Avet-Loiseau, Jill Corre, Philippe Moreau, Cyrille Touzeau
#1 CARTITUDE 1 Outstanding longterm efficacy with cilta-cel CAR-T in refractory myeloma median 6 prior lines of therapy.
5 year survival 50% 5 year PFS 33%
Title: Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Authors: Peter Voorhees, Tom Martin, Yi Lin, Adam Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus Berdeja, Binod Dhakal, Andrzej Jakubowiak, Samir Parekh, Hui Li, Rocio Montes de Oca, Huabin Sun, Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel, Sundar Jagannath
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023